AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29980320 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 Gy boost dose
Number of subjects: 2421
Study 29980320 — intervention group
Group type: COMPARATOR
Intervention: 16 Gy boost dose
Number of subjects: 2421
Study 26574791 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 746
Study 26574791 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg/day
Number of subjects: 746
Study 26574791 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 8 mg/day
Number of subjects: 746
Study 25172115 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (medication used to treat nocturia)
Number of subjects: 606
Study 25172115 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in FUSP
Number of subjects: 606
Study 22809601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen (10 mg/kg followed by 5 mg/kg at 24 hours and 48 hours)
Number of subjects: 64
Study 22809601 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 64
Study 22809601 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline at 1 mL/kg followed by 0.5 mL/kg at 24 hours and 48 hours)
Number of subjects: 64
Study 22809601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 19237683 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified treatment algorithm (initial therapy with low-dose ACE inhibitor/diuretic or ARB/diuretic combination, up-titration to highest dose, addition of calcium channel blocker, addition of non-first-line antihypertensive agent)
Number of subjects: 45
Study 19237683 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based management (Canadian Hypertension Education Program guidelines)
Number of subjects: 45
Study 19237683 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified treatment algorithm
Number of subjects: 45
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream without occlusion (group I)
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole 2% cream with occlusion (group II)
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiconazole 1% cream without occlusion (group III)
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiconazole 1% cream with occlusion (group IV)
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment approach
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after treatment
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical nail avulsion with topical antifungal agents
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion
Number of subjects: 40
Study 17573877 — intervention group
Group type: EXPERIMENTAL
Intervention: Total dystrophic onychomycosis (TDO)
Number of subjects: 40
Study 15068402 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (4 mg/kg/day for under 12 years, 3 mg/kg/day for over 12 years)
Number of subjects: 32
Study 15068402 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (1 mg/kg/day)
Number of subjects: 32
Study 12050245 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraphysiological recombinant human GH (rhGH; 0.2 IU.kg(‐1).d(‐1))
Number of subjects: 9
Study 10220796 — intervention group
Group type: COMPARATOR
Intervention: Normal cervical tissue
Number of subjects: 230
Study 10220796 — intervention group
Group type: COMPARATOR
Intervention: Low grade SILs
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: High grade SILs
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: Well‐differentiated squamous cell carcinomas (WDSCC)
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately differentiated squamous cell carcinomas (MDSCC)
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly differentiated carcinomas (PDSCC)
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: E6 protein expression
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16-infected lesions
Number of subjects: 230
Study 10220796 — intervention group
Group type: EXPERIMENTAL
Intervention: E6-expressing cells
Number of subjects: 230
Study 8541278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish-oil capsules (2.7 g n‐3 polyunsaturated fatty acids/d)
Number of subjects: 23
Study 8541278 — intervention group
Group type: COMPARATOR
Intervention: Olive-oil capsules (4 g/d)
Number of subjects: 23
Study 8541278 — intervention group
Group type: COMPARATOR
Intervention: No supplementation
Number of subjects: 23
Study 2240638 — intervention group
Group type: EXPERIMENTAL
Intervention: alfentanil/propofol (group P)
Number of subjects: 20
Study 2240638 — intervention group
Group type: COMPARATOR
Intervention: alfentanil/midazolam (group M)
Number of subjects: 20
Study 611326 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrand‐Ryhming Test administered at 50 rpm
Number of subjects: 30
Study 611326 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrand‐Ryhming Test administered at 80 rpm
Number of subjects: 30
Study 611326 — intervention group
Group type: COMPARATOR
Intervention: Maximum oxygen intake determined at the end of a graded exercise test
Number of subjects: 30
Study 611326 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between 50 and 80 rpm Astrand‐Ryhming protocols
Number of subjects: 30
Study 611326 — intervention group
Group type: EXPERIMENTAL
Intervention: Astrand‐Ryhming Tests at 80 rpm
Number of subjects: 30
Study 31101538 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 0
Study 31101538 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28379802 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 500
Study 28379802 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 500
Study 26558428 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flux Hemodialysis (HFHD)
Number of subjects: 50
Study 26558428 — intervention group
Group type: COMPARATOR
Intervention: Low-Flux Hemodialysis (LFHD)
Number of subjects: 50
Study 23633277 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial weight loss program
Number of subjects: 268
Study 23633277 — intervention group
Group type: COMPARATOR
Intervention: Primary care intervention
Number of subjects: 268
Study 21995388 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvant vaccine (ATIV)
Number of subjects: 4707
Study 21995388 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine without adjuvant (TIV)
Number of subjects: 4707
Study 21995388 — intervention group
Group type: COMPARATOR
Intervention: Control (noninfluenza) vaccines
Number of subjects: 4707
Study 21995388 — intervention group
Group type: EXPERIMENTAL
Intervention: ATIV vs TIV
Number of subjects: 4707
Study 19753604 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown diet (BD)
Number of subjects: 18
Study 19753604 — intervention group
Group type: COMPARATOR
Intervention: White diet
Number of subjects: 18
Study 17114599 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine plus aggressive debridement
Number of subjects: 504
Study 17114599 — intervention group
Group type: COMPARATOR
Intervention: Terbinafine alone
Number of subjects: 504
Study 15625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural tinnitus coping training (11 sessions)
Number of subjects: 77
Study 15625793 — intervention group
Group type: EXPERIMENTAL
Intervention: Habituation-based treatment (5 sessions)
Number of subjects: 77
Study 15625793 — intervention group
Group type: COMPARATOR
Intervention: Educational intervention (1 session)
Number of subjects: 77
Study 14697944 — intervention group
Group type: EXPERIMENTAL
Intervention: CyA, azathioprine, and prednisone
Number of subjects: 45
Study 14697944 — intervention group
Group type: COMPARATOR
Intervention: CyA and prednisone
Number of subjects: 45
Study 11048414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin administration (1 mg i.v. after ligation of the umbilical cord)
Number of subjects: 30
Study 11048414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin administration
Number of subjects: 30
Study 11048414 — intervention group
Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 30
Study 8530766 — intervention group
Group type: EXPERIMENTAL
Intervention: Early physical abuse
Number of subjects: 584
Study 8530766 — intervention group
Group type: EXPERIMENTAL
Intervention: Biased social information-processing patterns (encoding errors, hostile attributional biases, accessing of aggressive responses, positive evaluations of aggression)
Number of subjects: 584
Study 2256055 — intervention group
Group type: EXPERIMENTAL
Intervention: l-selenium-methionine (200 micrograms daily)
Number of subjects: 3
Study 2256055 — intervention group
Group type: COMPARATOR
Intervention: peaselenium (200 micrograms daily)
Number of subjects: 3
Study 2256055 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3
Study 6170414 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,2-anhydro-1-B-D-arabinofuranosyl-5-fluorocytosine (AAFC) and 6-thioguanine (TG)
Number of subjects: 51
Study 6170414 — intervention group
Group type: COMPARATOR
Intervention: L-6 regimen (control)
Number of subjects: 51
Study 6170414 — intervention group
Group type: EXPERIMENTAL
Intervention: L-12 protocol
Number of subjects: 51
Study 6170414 — intervention group
Group type: COMPARATOR
Intervention: L-6 protocol (control)
Number of subjects: 51
Study 31265338 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching program consisting of four 90‐minute classes
Number of subjects: 0
Study 31265338 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching program
Number of subjects: 0
Study 31265338 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 28371937 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg
Number of subjects: 244
Study 28371937 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.4 mg
Number of subjects: 244
Study 28371937 — intervention group
Group type: EXPERIMENTAL
Intervention: Naldemedine 0.1 mg
Number of subjects: 244
Study 28371937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 25426541 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (9.3 g of protein/566.4 KJ) plus exercise
Number of subjects: 53
Study 25426541 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 53
Study 25426541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Protein + Exercise and Exercise only)
Number of subjects: 53
Study 23602843 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment (ET) with dextranomer hyaluronic acid copolymer (Dx/HA)
Number of subjects: 41
Study 23602843 — intervention group
Group type: COMPARATOR
Intervention: Cohen's ureteral reimplantation (UR)
Number of subjects: 41
Study 21093286 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil dietary supplementation, 6 g/day (720 mg of DHA and 1,080 mg of EPA)
Number of subjects: 22
Study 21093286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 19436226 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% DHEA (Prasterone) 1.3 mL ovules
Number of subjects: 218
Study 19436226 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% DHEA (Prasterone) 1.3 mL ovules
Number of subjects: 218
Study 19436226 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% DHEA (Prasterone) 1.3 mL ovules
Number of subjects: 218
Study 19436226 — intervention group
Group type: COMPARATOR
Intervention: 0% DHEA (placebo)
Number of subjects: 218
Study 17318503 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 mg daily
Number of subjects: 26
Study 17318503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15540634 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental treatment (NDT) twice a week for 16 weeks
Number of subjects: 34
Study 15540634 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental treatment (NDT) five times a week for 16 weeks
Number of subjects: 34
Study 11572251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid external distraction (13 patients)
Number of subjects: 15
Study 11572251 — intervention group
Group type: COMPARATOR
Intervention: Face mask protraction (2 patients)
Number of subjects: 15
Study 9646600 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended outpatient treatment of 180 days
Number of subjects: 230
Study 9646600 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient treatment of 90 days
Number of subjects: 230
Study 7523545 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymun-Test CYFRA 21-1
Number of subjects: 0
Study 7523545 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard material prepared from a cytoskeleton fraction of cultivated MCF-7 cells
Number of subjects: 0
Study 31605667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency Ablation (CRFA)
Number of subjects: 33
Study 28913600 — intervention group
Group type: EXPERIMENTAL
Intervention: coll‐HA scaffold
Number of subjects: 100
Study 28913600 — intervention group
Group type: COMPARATOR
Intervention: BMS
Number of subjects: 100
Study 27429936 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral approach (Group A)
Number of subjects: 60
Study 27429936 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbuccal approach (Group B)
Number of subjects: 60
Study 27429936 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 60
Study 27429936 — intervention group
Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 60
Study 24494594 — intervention group
Group type: EXPERIMENTAL
Intervention: Conceptual instruction before problem solving
Number of subjects: 122
Study 24494594 — intervention group
Group type: COMPARATOR
Intervention: Conceptual instruction after problem solving
Number of subjects: 122
Study 22264615 — intervention group
Group type: EXPERIMENTAL
Intervention: PACU visit
Number of subjects: 45
Study 22264615 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no PACU visit)
Number of subjects: 45
Study 20701567 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Indigenous Games (TIG) delivered weekly for three months
Number of subjects: 0
Study 20701567 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18785544 — intervention group
Group type: EXPERIMENTAL
Intervention: WG-LASIK in Group A (negative vertical coma)
Number of subjects: 42
Study 18785544 — intervention group
Group type: EXPERIMENTAL
Intervention: WG-LASIK in Group B (positive vertical coma)
Number of subjects: 42
Study 18785544 — intervention group
Group type: COMPARATOR
Intervention: Classic LASIK in control group of Group A
Number of subjects: 42
Study 18785544 — intervention group
Group type: COMPARATOR
Intervention: Classic LASIK in control group of Group B
Number of subjects: 42
Study 16382125 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan alone
Number of subjects: 110
Study 16382125 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan and cyclophosphamide
Number of subjects: 110
Study 16382125 — intervention group
Group type: COMPARATOR
Intervention: Amifostine (randomly assigned group)
Number of subjects: 110
Study 16382125 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall therapy
Number of subjects: 110
Study 16382125 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 110
Study 16382125 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated pulmonary metastases
Number of subjects: 110
Study 16382125 — intervention group
Group type: EXPERIMENTAL
Intervention: Widespread disease
Number of subjects: 110
Study 14656033 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folic acid (5 mg/day)
Number of subjects: 0
Study 14656033 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-methyltetrahydrofolate directly into the brachial artery
Number of subjects: 0
Study 14656033 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10982541 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA
Number of subjects: 59
Study 10982541 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA
Number of subjects: 59
Study 10982541 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 59
Study 8633144 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL/sec
Number of subjects: 45
Study 8633144 — intervention group
Group type: COMPARATOR
Intervention: 3 mL/sec
Number of subjects: 45
Study 8633144 — intervention group
Group type: COMPARATOR
Intervention: 4.5 mL/sec
Number of subjects: 45
Study 8633144 — intervention group
Group type: COMPARATOR
Intervention: 6 mL/sec
Number of subjects: 45
Study 1424880 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol suspension aerosol (12 micrograms, twice daily)
Number of subjects: 186
Study 1424880 — intervention group
Group type: COMPARATOR
Intervention: Formoterol solution aerosol (12 micrograms, twice daily)
Number of subjects: 186
Study 2933119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline alone
Number of subjects: 62
Study 2933119 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen‐cyproterone acetate alone
Number of subjects: 62
Study 2933119 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tetracycline and oestrogen‐cyproterone acetate
Number of subjects: 62
Study 30729666 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Sema7A levels in AAS cases
Number of subjects: 210
Study 30729666 — intervention group
Group type: COMPARATOR
Intervention: Serum Sema7A levels in controls
Number of subjects: 210
Study 30729666 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Sema7A levels
Number of subjects: 210
Study 30729666 — intervention group
Group type: EXPERIMENTAL
Intervention: Each 1-standard deviation increase in Sema7A
Number of subjects: 210
Study 30527419 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate therapy
Number of subjects: 0
Study 30527419 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sodium bicarbonate therapy)
Number of subjects: 0
Study 27043272 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentle instruction
Number of subjects: 98
Study 27043272 — intervention group
Group type: COMPARATOR
Intervention: Harsh instruction
Number of subjects: 98
Study 24679222 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 2352
Study 24679222 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-backed tibial components
Number of subjects: 2352
Study 24679222 — intervention group
Group type: COMPARATOR
Intervention: Mobile bearings
Number of subjects: 2352
Study 21198857 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients
Number of subjects: 3224
Study 21198857 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients in those never completed high school
Number of subjects: 3224
Study 21198857 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients who are high school graduates
Number of subjects: 3224
Study 21198857 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients with partial college education
Number of subjects: 3224
Study 21198857 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients who completed college education
Number of subjects: 3224
Study 21198857 — intervention group
Group type: COMPARATOR
Intervention: White patients
Number of subjects: 3224
Study 21141077 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting carteolol hydrochloride 2% ophthalmic solution (LA), administered once a day
Number of subjects: 124
Study 21141077 — intervention group
Group type: COMPARATOR
Intervention: Original carteolol hydrochloride 2% ophthalmic solution (CA), administered twice a day
Number of subjects: 124
Study 17068328 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin on alternate days
Number of subjects: 22040
Study 17068328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22040
Study 16140593 — intervention group
Group type: COMPARATOR
Intervention: Topiramate (200-400 mg/day for adults or 5-9 mg/kg/day for children)
Number of subjects: 88
Study 16140593 — intervention group
Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 88
Study 12145765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose (75 g)
Number of subjects: 20
Study 12145765 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose (75 g)
Number of subjects: 20
Study 12145765 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (300 mL water with noncaloric flavoring)
Number of subjects: 20
Study 9469722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1
Number of subjects: 71
Study 9469722 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2
Number of subjects: 71
Study 9469722 — intervention group
Group type: COMPARATOR
Intervention: Both cohorts
Number of subjects: 71
Study 7638685 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-protein diet (0.4 g protein/kg/day supplemented with essential amino acids)
Number of subjects: 22
Study 7638685 — intervention group
Group type: COMPARATOR
Intervention: Conventional low-protein diet (0.6 g protein/kg/day)
Number of subjects: 22
Study 2203327 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-212 (20 mg)
Number of subjects: 17
Study 2203327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 576879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A
Number of subjects: 11
Study 576879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C
Number of subjects: 11
Study 576879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B
Number of subjects: 11
Study 576879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment D
Number of subjects: 11
Study 576879 — intervention group
Group type: COMPARATOR
Intervention: All Treatments
Number of subjects: 11